These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23047901)

  • 1. [Vitamin K antagonists: from discovery to pharmacogenetics].
    Moreau C; Loriot MA; Siguret V
    Ann Biol Clin (Paris); 2012 Oct; 70(5):539-51. PubMed ID: 23047901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pharmacogenetics of vitamin K antagonists: still a matter for discussion].
    Moreau C; Siguret V; Loriot MA
    Rev Med Interne; 2010 May; 31(5):361-8. PubMed ID: 20362363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms].
    Stępień E; Wypasek E; Branicka A; Undas A
    Kardiol Pol; 2010; 68 Suppl 5():S428-35. PubMed ID: 22134997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics aspects of oral anticoagulants therapy.
    Militaru FC; Vesa SC; Pop TR; Buzoianu AD
    J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].
    Siguret V
    Pathol Biol (Paris); 2007 Jul; 55(6):295-8. PubMed ID: 17611042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].
    Loriot MA; Beaune P
    Rev Prat; 2007 Jun; 57(12):1281-6. PubMed ID: 17717937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene.
    Wzorek J; Wypasek E; Awsiuk M; Potaczek DP; Undas A
    Blood Coagul Fibrinolysis; 2018 Jul; 29(5):429-434. PubMed ID: 29794812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.
    Brunner-Ziegler S; Jilma B; Magirr D; Sunder-Plassmann R; Giurgea GA; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
    Br J Haematol; 2014 Nov; 167(4):547-53. PubMed ID: 25142093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
    Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
    Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.
    Franchini M; Mengoli C; Cruciani M; Bonfanti C; Mannucci PM
    J Thromb Haemost; 2014 Sep; 12(9):1480-7. PubMed ID: 25040440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of vitamin K antagonists: useful or hype?
    Lippi G; Franchini M; Favaloro EJ
    Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of warfarin.
    Kamali F; Wynne H
    Annu Rev Med; 2010; 61():63-75. PubMed ID: 19686083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic predisposition to bleeding during oral anticoagulants treatment].
    Montes Díaz R; Nantes O; Molina E; Zozaya J; Hermida J
    An Sist Sanit Navar; 2008; 31(3):247-57. PubMed ID: 19165291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.
    Kovac MK; Maslac AR; Rakicevic LB; Radojkovic DP
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):558-63. PubMed ID: 20581661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists.
    Chatrou ML; Winckers K; Hackeng TM; Reutelingsperger CP; Schurgers LJ
    Blood Rev; 2012 Jul; 26(4):155-66. PubMed ID: 22520397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of oral anticoagulants: the opportunity for individualized drug treatment of greater safety.
    Loriot MA; Beaune P
    Per Med; 2007 Nov; 4(4):413-421. PubMed ID: 29793282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
    Loriot MA; Beaune P
    Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Modeling Insights into Human VKORC1 Phenotypes.
    Czogalla KJ; Watzka M; Oldenburg J
    Nutrients; 2015 Aug; 7(8):6837-51. PubMed ID: 26287237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone.
    Moreau C; Pautas E; Duverlie C; Berndt C; Andro M; Mahé I; Emmerich J; Lacut K; Le Gal G; Peyron I; Gouin-Thibault I; Golmard JL; Loriot MA; Siguret V
    Thromb Haemost; 2014 Apr; 111(4):705-12. PubMed ID: 24337438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin K antagonists--current concepts and challenges.
    Moualla H; Garcia D
    Thromb Res; 2011 Sep; 128(3):210-5. PubMed ID: 21570107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.